China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
NEW YORK, April 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Lion Biotechnologies, Inc. ("Lion Biotechnologies") (NASDAQ:LBIO) securities between November 14, 2013 and April 10, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) through its former CEO Manish Singh, Lion was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites, as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Lion Biotechnologies you have until June 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/lion-biotechnologies-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
